Some potential explanations include mutations in CCND1 that significantly alter the 3D protein structure of the IHC antibody-binding epitope, suboptimal staining due to technical issues with instrumentation or IHC antibody, and pre-analytical factors such as poor formalin fixation, or low tumor cell viability. This evidence concerns the gene CCND1 and neoplasm.